U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H72N2O12
Molecular Weight 748.986
Optical Activity UNSPECIFIED
Defined Stereocenters 18 / 18
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZITHROMYCIN ANHYDROUS

SMILES

CC[C@]1([H])[C@](C)([C@@]([H])([C@@]([H])(C)N(C)C[C@]([H])(C)C[C@](C)([C@@]([H])([C@@]([H])(C)[C@@]([H])([C@@]([H])(C)C(=O)O1)O[C@@]2([H])C[C@](C)([C@]([H])([C@]([H])(C)O2)O)OC)O[C@@]3([H])[C@@]([H])([C@]([H])(C[C@@]([H])(C)O3)N(C)C)O)O)O)O

InChI

InChIKey=MQTOSJVFKKJCRP-BICOPXKESA-N
InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1

HIDE SMILES / InChI
Azithromycin is one of the world's best-selling antibiotics, used to treat or prevent certain bacterial infections: Acute bacterial exacerbations of chronic bronchitis in adults; acute bacterial sinusitis in adults; uncomplicated skin and skin structure infections in adults; urethritis and cervicitis in adults; genital ulcer disease in men; acute otitis media in pediatric patients; community-acquired pneumonia in adults and pediatric patients; pharyngitis/tonsillitis in adults and pediatric patients. Azithromycin should not be used in patients with pneumonia who are judged inappropriate for oral therapy because of moderate to severe illness or risk factors. A team of researchers at the Croatian pharmaceutical company Pliva, discovered azithromycin in 1980. It was patented in 1981. In 1986, Pliva and Pfizer signed a licensing agreement, which gave Pfizer exclusive rights for the sale of azithromycin in Western Europe and the United States. Pliva put its azithromycin on the market in Central and Eastern Europe under the brand name of Sumamed in 1988. Pfizer launched azithromycin under Pliva's license in other markets under the brand name Zithromax in 1991. Azithromycin is a semi-synthetic macrolide antibiotic of the azalide class. Like other macrolide antibiotics, azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit of the bacterial 70S ribosome. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the process of translation. Its effects may be bacteriostatic or bactericidal depending of the organism and the drug concentration. Its long half-life, which enables once daily dosing and shorter administration durations, is a property distinct from other macrolides.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ZITHROMAX

Approved Use

Azithromycin Tablets, USP are indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients: (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.

Launch Date

688953600000
Curative
ZITHROMAX

Approved Use

Azithromycin Tablets, USP are indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients: (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.

Launch Date

688953600000
Curative
ZITHROMAX

Approved Use

Azithromycin Tablets, USP are indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients: (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.

Launch Date

688953600000
Curative
ZITHROMAX

Approved Use

Azithromycin Tablets, USP are indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients: (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.

Launch Date

688953600000
Curative
ZITHROMAX

Approved Use

Azithromycin Tablets, USP are indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients: (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.

Launch Date

688953600000
Curative
ZITHROMAX

Approved Use

Azithromycin Tablets, USP are indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients: (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.

Launch Date

688953600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.39 μg/L
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZITHROMYCIN ANHYDROUS serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.94 mg/L
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZITHROMYCIN ANHYDROUS serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.54 μg/mL
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AZITHROMYCIN ANHYDROUS serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.5 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZITHROMYCIN ANHYDROUS unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.94 mg × h/L
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZITHROMYCIN ANHYDROUS serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10 mg × h/L
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZITHROMYCIN ANHYDROUS serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17.4 μg × h/mL
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AZITHROMYCIN ANHYDROUS serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.3 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZITHROMYCIN ANHYDROUS unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
71.8 h
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AZITHROMYCIN ANHYDROUS serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
71%
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AZITHROMYCIN ANHYDROUS serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
71%
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AZITHROMYCIN ANHYDROUS unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
2 g 1 times / day single, oral
Highest studied dose
dose: 2 g 1 times / day
route: oral
experiment_type: single
dose_type: Highest studied dose
co-adm with
    data_source:
    https://www.nejm.org/doi/full/10.1056/nejm199209243271304
    unhealthy, 25.2 (16-50)
    population: unhealthy
    age: 25.2 (16-50)
    sex: M+F
    food_status:
    n:
    data_source:
    https://www.nejm.org/doi/full/10.1056/nejm199209243271304
    0.5 g 1 times / day single, intravenous
    Recommended
    dose: 0.5 g 1 times / day
    route: intravenous
    experiment_type: single
    dose_type: Recommended
    co-adm with
      data_source:
      https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236(97)90098-9
      healthy, 42 (25-56)
      population: healthy
      age: 42 (25-56)
      sex:
      food_status:
      n:
      data_source:
      https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236(97)90098-9
      1 % 2 times / day multiple, ophthalmic
      Recommended
      dose: 1 % 2 times / day
      route: ophthalmic
      experiment_type: multiple
      dose_type: Recommended
      co-adm with
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
        unhealthy, adult
        population: unhealthy
        age: adult
        sex: M+F
        food_status:
        n:
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
        Disc. AE: Iritis, Conjunctivitis bacterial...
        AEs leading to
        discontinuation/dose reduction:​
        Iritis (2 times / day)
        Conjunctivitis bacterial (2 times / day)
        Conjunctivitis (2 times / day)
        Irritability (2 times / day)
        Herpes zoster (2 times / day)

        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
        1 % 2 times / day multiple, ophthalmic
        Recommended
        dose: 1 % 2 times / day
        route: ophthalmic
        experiment_type: multiple
        dose_type: Recommended
        co-adm with
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
          unhealthy, adult
          population: unhealthy
          age: adult
          sex: M+F
          food_status:
          n:
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
          Disc. AE: Sinusitis, Throat infection...
          AEs leading to
          discontinuation/dose reduction:​
          Sinusitis (2 times / day)
          Throat infection (2 times / day)
          Upper respiratory tract infection (2 times / day)

          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
          0.5 g 2 times / day multiple, intravenous
          Recommended
          dose: 0.5 g 2 times / day
          route: intravenous
          experiment_type: multiple
          dose_type: Recommended
          co-adm with
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
            unknown, adult
            population: unknown
            age: adult
            sex: M+F
            food_status:
            n:
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
            Other AEs: Angioedema, Anaphylaxis...
            Other AEs:
            Angioedema (2 times / day)
            Anaphylaxis (2 times / day)
            Stevens Johnson syndrome (2 times / day)
            Toxic epidermal necrolysis (2 times / day)

            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
            AEs

            AEs

            AESignificanceDosePopulation
            Anaphylaxis
            0.5 g 2 times / day multiple, intravenous
            Recommended
            dose: 0.5 g 2 times / day
            route: intravenous
            experiment_type: multiple
            dose_type: Recommended
            co-adm with
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
              unknown, adult
              population:
              age:
              sex:
              food_status:
              n:
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
              Angioedema
              0.5 g 2 times / day multiple, intravenous
              Recommended
              dose: 0.5 g 2 times / day
              route: intravenous
              experiment_type: multiple
              dose_type: Recommended
              co-adm with
                data_source:
                https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
                unknown, adult
                population:
                age:
                sex:
                food_status:
                n:
                data_source:
                https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
                Stevens Johnson syndrome
                0.5 g 2 times / day multiple, intravenous
                Recommended
                dose: 0.5 g 2 times / day
                route: intravenous
                experiment_type: multiple
                dose_type: Recommended
                co-adm with
                  data_source:
                  https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
                  unknown, adult
                  population:
                  age:
                  sex:
                  food_status:
                  n:
                  data_source:
                  https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
                  Toxic epidermal necrolysis
                  0.5 g 2 times / day multiple, intravenous
                  Recommended
                  dose: 0.5 g 2 times / day
                  route: intravenous
                  experiment_type: multiple
                  dose_type: Recommended
                  co-adm with
                    data_source:
                    https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
                    unknown, adult
                    population:
                    age:
                    sex:
                    food_status:
                    n:
                    data_source:
                    https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf
                    Conjunctivitis bacterial
                    Disc. AE
                    1 % 2 times / day multiple, ophthalmic
                    Recommended
                    dose: 1 % 2 times / day
                    route: ophthalmic
                    experiment_type: multiple
                    dose_type: Recommended
                    co-adm with
                      data_source:
                      https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                      unhealthy, adult
                      population:
                      age:
                      sex:
                      food_status:
                      n:
                      data_source:
                      https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                      Conjunctivitis
                      Disc. AE
                      1 % 2 times / day multiple, ophthalmic
                      Recommended
                      dose: 1 % 2 times / day
                      route: ophthalmic
                      experiment_type: multiple
                      dose_type: Recommended
                      co-adm with
                        data_source:
                        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                        unhealthy, adult
                        population:
                        age:
                        sex:
                        food_status:
                        n:
                        data_source:
                        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                        Herpes zoster
                        Disc. AE
                        1 % 2 times / day multiple, ophthalmic
                        Recommended
                        dose: 1 % 2 times / day
                        route: ophthalmic
                        experiment_type: multiple
                        dose_type: Recommended
                        co-adm with
                          data_source:
                          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                          unhealthy, adult
                          population:
                          age:
                          sex:
                          food_status:
                          n:
                          data_source:
                          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                          Iritis
                          Disc. AE
                          1 % 2 times / day multiple, ophthalmic
                          Recommended
                          dose: 1 % 2 times / day
                          route: ophthalmic
                          experiment_type: multiple
                          dose_type: Recommended
                          co-adm with
                            data_source:
                            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                            unhealthy, adult
                            population:
                            age:
                            sex:
                            food_status:
                            n:
                            data_source:
                            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                            Irritability
                            Disc. AE
                            1 % 2 times / day multiple, ophthalmic
                            Recommended
                            dose: 1 % 2 times / day
                            route: ophthalmic
                            experiment_type: multiple
                            dose_type: Recommended
                            co-adm with
                              data_source:
                              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                              unhealthy, adult
                              population:
                              age:
                              sex:
                              food_status:
                              n:
                              data_source:
                              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                              Sinusitis
                              Disc. AE
                              1 % 2 times / day multiple, ophthalmic
                              Recommended
                              dose: 1 % 2 times / day
                              route: ophthalmic
                              experiment_type: multiple
                              dose_type: Recommended
                              co-adm with
                                data_source:
                                https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                                unhealthy, adult
                                population:
                                age:
                                sex:
                                food_status:
                                n:
                                data_source:
                                https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                                Throat infection
                                Disc. AE
                                1 % 2 times / day multiple, ophthalmic
                                Recommended
                                dose: 1 % 2 times / day
                                route: ophthalmic
                                experiment_type: multiple
                                dose_type: Recommended
                                co-adm with
                                  data_source:
                                  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                                  unhealthy, adult
                                  population:
                                  age:
                                  sex:
                                  food_status:
                                  n:
                                  data_source:
                                  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                                  Upper respiratory tract infection
                                  Disc. AE
                                  1 % 2 times / day multiple, ophthalmic
                                  Recommended
                                  dose: 1 % 2 times / day
                                  route: ophthalmic
                                  experiment_type: multiple
                                  dose_type: Recommended
                                  co-adm with
                                    data_source:
                                    https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                                    unhealthy, adult
                                    population:
                                    age:
                                    sex:
                                    food_status:
                                    n:
                                    data_source:
                                    https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf
                                    Overview

                                    Overview

                                    CYP3A4CYP2C9CYP2D6hERG

                                    Drug as perpetrator​Drug as victimTox targets

                                    Tox targets

                                    TargetModalityActivityMetaboliteClinical evidence
                                    Sourcing

                                    Sourcing

                                    Vendor/AggregatorIDURL
                                    PubMed

                                    PubMed

                                    TitleDatePubMed
                                    Antibiotic prophylaxis for intrauterine contraceptive device insertion.
                                    2001
                                    Comparative in vitro activity of thiamphenicol-glycinate and thiamphenicol-glycinate-acetylcysteinate and other antimicrobials against respiratory pathogens.
                                    2001
                                    Review of macrolides and ketolides: focus on respiratory tract infections.
                                    2001
                                    The SAFE strategy for the elimination of trachoma by 2020: will it work?
                                    2001
                                    Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children.
                                    2001
                                    Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal.
                                    2001
                                    [Skin eruptions due to azithromycin (Azadose-Zithromax) and infectious mononucleosis].
                                    2001 Apr
                                    Duration of clinical symptoms in female patients with acute urethral syndrome caused by Chlamydia trachomatis treated with azithromycin or doxycycline.
                                    2001 Apr
                                    Mycobacterium marinum infection in a lung transplant recipient.
                                    2001 Apr
                                    Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure.
                                    2001 Apr
                                    Comparative efficacy of new investigational agents against Helicobacter pylori.
                                    2001 Apr
                                    In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria.
                                    2001 Apr
                                    In vitro effects of azithromycin on Salmonella typhi: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula.
                                    2001 Apr
                                    Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections.
                                    2001 Apr
                                    Severe babesiosis in Long Island: review of 34 cases and their complications.
                                    2001 Apr 15
                                    Azithromycin and pelvic inflammatory disease in the Northern Territory.
                                    2001 Apr 2
                                    Clindamycin suspension and endocarditis prophylaxis.
                                    2001 Apr 28
                                    [Isolation of Vibrio strains in French coastal waters and infection with Vibrio cholerae non-O1/non-O139].
                                    2001 Apr 7
                                    Oligella ureolytica in blood culture: contaminant or infection?
                                    2001 Feb
                                    Azithromycin: a new 15-membered macrolide.
                                    2001 Feb
                                    Identification of parasitoses in a child burial from Adak Island (Central Aleutian Islands, Alaska).
                                    2001 Feb
                                    Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris.
                                    2001 Jan
                                    Donovanosis: an update.
                                    2001 Jul
                                    Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens.
                                    2001 Jul 15
                                    Inhibitory and bactericidal effects of telithromycin (HMR 3647, RU 56647) and five comparative antibiotics, used singly and in combination, against vancomycin-resistant and vancomycin-susceptible enterococci.
                                    2001 Jul-Aug
                                    The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy.
                                    2001 Jun
                                    A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy.
                                    2001 Jun
                                    Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
                                    2001 Jun
                                    The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages.
                                    2001 Jun
                                    Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila.
                                    2001 Jun 1
                                    Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin).
                                    2001 Jun 15
                                    A family cluster of Chlamydia trachomatis infection.
                                    2001 Jun 16
                                    Postantibiotic suppression effect of macrolides on the expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis.
                                    2001 Mar
                                    Comparative serum bactericidal activity of clarithromycin and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae.
                                    2001 Mar
                                    In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.
                                    2001 Mar
                                    Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
                                    2001 Mar
                                    In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.
                                    2001 Mar
                                    Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS.
                                    2001 Mar 30
                                    Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective.
                                    2001 Mar-Apr
                                    [Experimental infection in mice by Plasmodium berghei: an evidence of antiparasitic action of azithromycin].
                                    2001 Mar-Apr
                                    [Pharmacological and pharmacokinetic properties of azithromycin (Zithromac), a novel 15-membered ring macrolide antibacterial agent].
                                    2001 May
                                    The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial.
                                    2001 May
                                    Inoculation of two genotypes of Hemobartonella felis (California and Ohio variants) to induce infection in cats and the response to treatment with azithromycin.
                                    2001 May
                                    The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
                                    2001 May
                                    [Chemoprophylaxis of meningococcal disease with azithromycin and ciprofloxacin].
                                    2001 May
                                    Decreased susceptibility to azithromycin and erythromycin mediated by a novel mtr(R) promoter mutation in Neisseria gonorrhoeae.
                                    2001 May
                                    The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae.
                                    2001 May
                                    When to suspect and how to monitor babesiosis.
                                    2001 May 15
                                    Solid-phase synthesis of macrolide analogues.
                                    2001 May-Jun
                                    A multicenter study of the antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal.
                                    2001 Spring
                                    Patents

                                    Sample Use Guides

                                    Community-acquired pneumonia (mild severity); Pharyngitis/tonsillitis (second-line
                                    Route of Administration: Oral
                                    Azithromycin can benefit treating allergic airway inflammation and remodeling. Azithromycin significantly reduced the inflammation score, peribronchial smooth muscle layer thickness, epithelial thickening and goblet cell metaplasia, and effectively suppressed apoptotic index (AI) of airway epithelium. Moreover, the increasing mRNA and protein expressions of Caspase-3 and Bax/Bcl-2 ratio in lung tissue were all significantly decreased in azithromycin-treated rats. In vitro, azithromycin significantly suppressed TGF-β1-induced BEAS-2B cells apoptosis and reversed TGF-β1 elevated Caspase-3 mRNA level and Bax/Bcl-2 ratio.
                                    Name Type Language
                                    AZITHROMYCIN ANHYDROUS
                                    Common Name English
                                    ZITHROMAC
                                    Brand Name English
                                    ARUZILINA
                                    Brand Name English
                                    CP 62993
                                    Code English
                                    NSC-758625
                                    Code English
                                    ZYTHROMAX
                                    Brand Name English
                                    HEMOMYCIN
                                    Common Name English
                                    N-METHYL-11-AZA-10-DEOXO-10-DIHYDROERYTHROMYCIN A
                                    Common Name English
                                    AZITHROCIN
                                    Brand Name English
                                    9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A
                                    Common Name English
                                    AZITHROMYCIN [HSDB]
                                    Common Name English
                                    ANHYDROUS AZITHROMYCIN
                                    Common Name English
                                    XZ 450
                                    Code English
                                    DURASITE
                                    Brand Name English
                                    XITHRONE
                                    Common Name English
                                    AZIROMYCIN
                                    Common Name English
                                    AZASITE
                                    Brand Name English
                                    CP-62,993
                                    Code English
                                    AZIWIN
                                    Brand Name English
                                    CP-62993
                                    Code English
                                    AZITHROMYCIN [INN]
                                    Common Name English
                                    SUMAMED
                                    Brand Name English
                                    XZ 405
                                    Code English
                                    AZITHROMYCIN [MI]
                                    Common Name English
                                    XZ-450
                                    Code English
                                    MACROZIT
                                    Brand Name English
                                    TROZOCINA
                                    Brand Name English
                                    Classification Tree Code System Code
                                    WHO-ATC J01FA10
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    NDF-RT N0000175935
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    NCI_THESAURUS C261
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    Code System Code Type Description
                                    HSDB
                                    7205
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY
                                    DRUG BANK
                                    DB00207
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY
                                    EPA CompTox
                                    83905-01-5
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY
                                    NCI_THESAURUS
                                    C76213
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY
                                    CAS
                                    83905-01-5
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY
                                    MERCK INDEX
                                    M2177
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY Merck Index
                                    INN
                                    6197
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY
                                    EVMPD
                                    SUB90954
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY
                                    EVMPD
                                    SUB05660MIG
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY
                                    FDA UNII
                                    J2KLZ20U1M
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY
                                    PUBCHEM
                                    447043
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY
                                    RXCUI
                                    1299904
                                    Created by admin on Fri Jun 25 22:03:19 UTC 2021 , Edited by admin on Fri Jun 25 22:03:19 UTC 2021
                                    PRIMARY RxNorm